Lilly's Phase II retatrutide trial shows highest weight loss

The race to provide obesity treatments on Monday seems have raised the bar, as an experimental weight-loss compound from US pharma major Eli Lilly (NYSE: LLY) yielded the strongest results of any treatment seen so far.

Lilly announced new Phase II data from retatrutide, an experimental drug that targets three hormones. At 24 weeks, retatrutide (1mg, 4mg, 8mg or 12mg) met the primary endpoint for the efficacy estimand in participants living with obesity or overweight without diabetes, demonstrating a mean weight reduction up to 17.5% (41.2 lb. or 18.7 kg).

However, in a secondary endpoint, retatrutide demonstrated a mean weight reduction up to 24.2% (57.8 lb. or 26.2 kg) at the end of the 48-week treatment duration.